The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1644
ISSUE1644
February 21, 2022
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
February 21, 2022 (Issue: 1644)
The FDA has approved Apretude (ViiV Healthcare),
an IM extended-release (ER) formulation of the integrase
strand transfer inhibitor (INSTI) cabotegravir,
for use every 2 months to prevent sexually acquired
HIV-1 infection in at-risk adolescents...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.